Abstract

Huseyin Naci and Jonathan Cylus provide arguments for how to improve the regulation concerning pharmaceutical drugs. Since drugs are not assessed relative to alternatives on the market, they claim it becomes more difficult to accurately evaluate a drug’s successes and harms. Increased innovation and a more streamlined delivery of information are some of the benefits they attribute to more rigorous drug regulations.